From Nature:
The drug discovery and development landscape is plagued by inefficiency, risk and astronomical cost. Clinical success rates languish below 10%, convoluted in- and out-licensing workflows erode precious patent life, and industry estimates suggest that biopharma companies write off some $15 billion every year on deprioritized candidates. At the same time, more than 90% of oncology drugs—and a significant proportion of all therapeutics—will lose patent exclusivity within the next five years, creating a looming innovation shortfall. Partex is here to bridge that gap. As the world’s largest artificial intelligence (AI)-driven drug-asset manager, Partex supercharges pipelines, resurrects shelved compounds and slashes development time to clinic—revolutionizing discovery and development at every step.
From data ocean to drug assets
At the heart of Partex lies an unparalleled ocean of real-time data—650 terabytes of public sources, 270 terabytes of proprietary studies and more than 2 million de-identified patient records—which are continuously updated and fully auditable (Fig. 1). More than 200 specialized AI models roam this data landscape, rapidly delivering actionable insights across the entire research and development (R&D) continuum.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.